Martine Rothblatt, PhD, JD
Chairman & CEO
Dr. Martine Rothblatt founded Lung Biotechnology, as well as our parent company, United Therapeutics, in order to develop therapies for orphan diseases such as PAH.
She earned her PhD in medical ethics from the Royal London School of Medicine and Dentistry, Queen Mary College, University of London and also obtained JD and MBA degrees from the University of California in Los Angeles. Prior to entering the life sciences field, Dr. Rothblatt was active in satellite communications, founding Sirius XM Satellite Radio and serving as its Chairman and CEO. She has also published many books, including Your Life or Mine: How Geoethics Can Resolve the Conflict Between Public and Private Interests in Xenotransplantation.
Marc I. Lorber, MD
Chief Medical Officer / Senior Vice President, Clinical Development and XenoLung
Marc Lorber has been Chief Medical Officer and Senior Vice President, Clinical Development, XenoLung, since August 2012.
Prior to joining Lung Biotechnology, he served in several drug development roles at Novartis, most recently as Vice President and Therapeutic Area Head, responsible for transplantation, nephrology and autoimmunity indications in the IHC Global Development Franchise. Prior to joining Novartis in 2007, Dr. Lorber was Chief of Organ Transplantation and Immunology at Yale University School of Medicine for nearly 21 years, where he was also Professor of Surgery and Pathology. He was an active researcher and busy clinical transplant surgeon; he has published extensively and delivered scientific addresses in his areas of expertise across the world. Dr. Lorber is Past President of the American Society of Transplant Surgeons, a past member of the Board of Directors and Secretary of the United Network for Organ Sharing, and he served on the Advisory Committee for Organ Transplantation, U.S. Department of Health and Human Services.
Vice President of Clinical Development & Regulatory Processes
Aimee Smart is the Vice President of Clinical Development & Regulatory Processes at Lung Biotechnology. Ms. Smart brings with her more than two decades of leadership experience in regulatory affairs and drug development along with a wealth of knowledge in creating and implementing strategies with the goal of successful US and international regulatory filings. Prior to Lung Biotechnology, she was the Director of Regulatory Affairs for VIRxSYS Corporation and worked in Regulatory Affairs at Human Genome Sciences, Nabi Biopharmaceuticals, and Cato Research. In her current position, Ms. Smart leads Regulatory and Clinical Research and Development at both Lung Biotechnology and Lung Bioengineering.
Director, Organ Manufacturing
Luis Alvarez, PhD joined Lung Biotechnology in 2017 as the Director of Organ Manufacturing. Prior to joining Lung Biotechnology, Luis was an Academy Professor in the Department of Chemistry and Life Science at the United States Military Academy, West Point. Prior to his academic appointment Luis served as the co-founding Deputy Director of the Department of Defense Regenerative Medicine Program Office. In this capacity, he oversaw a portfolio of regenerative therapeutics in preclinical and clinical development. Luis also led the Department of Defense nerve agent recombinant countermeasure program. Previously, he served as an intelligence officer, with tours in South Korea and in Operation Iraqi Freedom where he was a awarded the Bronze Star Medal and the Combat Action Badge. Luis completed a PhD in biological engineering at the Massachusetts Institute of Technology where he was a Hertz Foundation Fellow.